The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling (VALID).
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2015
At a glance
- Drugs Valsartan (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms VALID
- 01 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned End Date changed from 1 Dec 2011 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 22 Nov 2011 Trial protocol published in the Trials. Results will be available in 2012.